A new survey by Strategy&, PwC’s strategy consulting business, has found that pharmaceutical executives generally aren’t inclined to spend more to fight fakes, despite their awareness that current measures don’t go far enough. Not only do these executives misjudge their own vulnerability, but they also overlook the opportunities awaiting those that capitalize on rapidly evolving anti-counterfeiting technologies that do more than improve on existing supply chain safeguards. Companies that adopt these technologies will reap a range of new benefits, and gain an edge over rivals relying on yesterday’s solutions.
With this in mind, we decided to take a look at the top three reasons to capitalize on new anti-counterfeiting and brand protection technologies this year.
This video takes a look at INTERPOL's largest counterfeit seizure in 2018. This year's Pangea enforcement operation, which took place October 9-16, focused on taking down rogue online pharmacies. Take a look at the video!
For the video sent to your inbox, please email firstname.lastname@example.org